5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Last Updated: Thursday, April 6, 2023

The estimated 5-year overall survival rate for patients with refractory large B-cell lymphoma who were treated with axicabtagene ciloleucel in the phase ZUMA-1 trial was 42.6%. No new treatment-related serious adverse events or deaths were observed during this longer follow-up.

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

The Lancet

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial

Human Vaccines & Immunotherapeutics

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

New England Journal of Medicine Evidence

CD19 CAR T-cell therapy in autoimmune disease–A case series with follow-up

New England Journal of Medicine Evidence

CAR T-cell immunotherapy in minority patients with lymphoma

Blood Cancer Journal

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

The ASCO Post

Novel CAR T-cell therapy under study in relapsed or refractory non-Hodgkin lymphoma

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

CAR T-Cell Therapy Resource Center

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

The Lancet

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial

Human Vaccines & Immunotherapeutics

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

New England Journal of Medicine Evidence

CD19 CAR T-cell therapy in autoimmune disease–A case series with follow-up

New England Journal of Medicine Evidence

CAR T-cell immunotherapy in minority patients with lymphoma

Blood Cancer Journal

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

The ASCO Post

Novel CAR T-cell therapy under study in relapsed or refractory non-Hodgkin lymphoma

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Neurologic Toxicity Post-CAR T-Cell Therapy and CRS: Differentiating Symptoms and Individual Management

Fast Facts #12: BCMA Targets